Vital Therapies Inc (VTL) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Vital Therapies Inc (NASDAQ:VTL) from a sell rating to a hold rating in a research report report published on Friday, April 14th.

According to Zacks, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. “

Other equities analysts have also issued research reports about the company. Canaccord Genuity set a $10.00 price objective on Vital Therapies and gave the company a buy rating in a research note on Monday, January 2nd. BTIG Research restated a hold rating on shares of Vital Therapies in a research report on Friday, March 10th.

Vital Therapies (NASDAQ:VTL) traded up 21.15% during midday trading on Friday, hitting $3.15. The stock had a trading volume of 182,059 shares. Vital Therapies has a 52 week low of $2.55 and a 52 week high of $8.38. The company has a 50-day moving average price of $3.67 and a 200-day moving average price of $4.56. The stock’s market cap is $132.95 million.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.02. During the same quarter last year, the firm posted ($0.31) earnings per share. Equities analysts expect that Vital Therapies will post ($1.80) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/05/19/vital-therapies-inc-vtl-rating-increased-to-hold-at-zacks-investment-research-updated-updated-updated.html.

In related news, Director Muneer A. Satter bought 3,750,000 shares of the stock in a transaction dated Monday, March 27th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $15,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 29.88% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its stake in shares of Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after buying an additional 1,157 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock worth $352,000 after buying an additional 9,120 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Vital Therapies by 5.8% in the first quarter. Geode Capital Management LLC now owns 172,210 shares of the company’s stock worth $688,000 after buying an additional 9,448 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Vital Therapies by 1.6% in the first quarter. Vanguard Group Inc. now owns 845,858 shares of the company’s stock worth $3,383,000 after buying an additional 13,654 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares during the last quarter. 26.68% of the stock is currently owned by hedge funds and other institutional investors.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

5 Day Chart for NASDAQ:VTL

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Vital Therapies Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vital Therapies Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit